Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use

Cancer statistics, 2011

Siegel, R. L., Ward, E., Brawley, O. W., & Jemal, A. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20121 · Cited by 4,075 · see citing works

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782 · see citing works

Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,316 · see citing works

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

Cheson, B. D., Bennett, J. M., Grever, M. R., Kay, N. E., Keating, M., O’Brien, S. J., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,815 · see citing works

Reshaping human antibodies for therapy

Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562 · see citing works

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Keating, M. J., Flinn, I. W., Jain, V. K., Binet, J., Hillmen, P., Byrd, J. C., Albitar, M. X., Brettman, L. R., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 947 · see citing works

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920 · see citing works

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807 · see citing works

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Lannutti, B. J., Meadows, S. A., Herman, S. E. M., Kashishian, A., Steiner, B. H., Johnson, A. J., Byrd, J. C., Tyner, J. W., Loriaux, M., Deininger, M., et al. (2010) · Blood · doi:10.1182/blood-2010-03-275305 · Cited by 726 · see citing works

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

Hale, G., Clark, M., Marcus, R. E., Winter, G. P., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688 · see citing works

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640 · see citing works

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

Hillmen, P., Skotnicki, A. B., Robak, T., Jaksic, B. S., Dmoszyńska, A., Wu, J., Sirard, C. A., & Mayer, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9098 · Cited by 560 · see citing works

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

de Rooij, M. F. M., Kuil, A., Geest, C. R., Eldering, E., Chang, B. Y., Buggy, J. J., Pals, S. T., & Spaargaren, M. (2012) · Blood · doi:10.1182/blood-2011-11-390989 · Cited by 558 · see citing works

The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

Hoellenriegel, J., Meadows, S. A., Sivina, M., Wierda, W. G., Kantarjian, H. M., Keating, M. J., Giese, N. A., O'Brien, S. M., Yu, A. S., Miller, L. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352492 · Cited by 548 · see citing works

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

Österborg, A., Dyer, M. J. S., Bunjes, D. W., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1567 · Cited by 511 · see citing works

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., Möllgård, L., Rebello, P., Hale, G., Waldmann, H., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0159 · Cited by 497 · see citing works

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Moreton, P., Kennedy, B., Lucas, G. S., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J. E., Oscier, D. G., Fegan, C., Rawstron, A. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.021 · Cited by 418 · see citing works

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Lozanski, G., Heerema, N. A., Flinn, I. W., Smith, L., Harbison, J., Webb, J. L., Moran, M. E., Lucas, M. S., Lin, T. S., Hackbarth, M. L., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3729 · Cited by 397 · see citing works

Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

Cheson, B. D., Bennett, J. M., Rai, K. R., Grever, M. R., Kay, N. E., Schiffer, C. A., Oken, M. M., Keating, M. J., Boldt, D. H., Kempin, S. J., et al. (1988) · American Journal of Hematology · doi:10.1002/ajh.2830290307 · Cited by 389 · see citing works

Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement

Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A., & Waldmann, H. (1983) · Blood · doi:10.1182/blood.v62.4.873.873 · Cited by 360 · see citing works

Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine

R., K., Freter, C. E., Mercier, R., Cooper, M. R., Mitchell, B. S., Stadtmauer, E. A., Santabarbara, P., Wacker, B., & Brettman, L. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.119 · Cited by 306 · see citing works

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

Martin, S. I., Marty, F. M., Fiumara, K., Treon, S. P., Gribben, J. G., & Baden, L. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504811 · Cited by 270 · see citing works

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stilgenbauer, S., Zenz, T., Winkler, D. F. H., Bühler, A., Schlenk, R. F., Groner, S., Busch, R. M., Hensel, M., Dührsen, U., Finke, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1128 · Cited by 269 · see citing works

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Lundin, J., Österborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A. A., Gisselbrecht, C., Huhn, D., Jaeger, U., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3257 · Cited by 255 · see citing works

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Faderl, S. H., Thomas, D. A., O'Brien, S. M., Garcia‐Manero, G., Kantarjian, H. M., Giles, F. J., Koller, C. A., Ferrajoli, A., Verstovšek, S., Pro, B., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1952 · Cited by 251 · see citing works

Humanized CD52 monoclonal antibody campath‐1H as first‐line treatment in chronic lymphocytic leukaemia

Österborg, A., Fassas, Α., Anagnostopoulos, Α., Dyer, M. J. S., Catovsky, D., & Mellstedt, H. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.450989.x · Cited by 227 · see citing works

Campath-1H–Induced Complete Remission of Chronic Lymphocytic Leukemia despitep53Gene Mutation and Resistance to Chemotherapy

Stilgenbauer, S., & Döhner, H. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208083470619 · Cited by 218 · see citing works

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

Xia, M., Hale, G., Lifely, M. R., Ferguson, M. A. J., Campbell, D. G., Packman, L. C., & Waldmann, H. (1993) · Biochemical Journal · doi:10.1042/bj2930633 · Cited by 213 · see citing works

Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinköthe, T., Stützer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9950 · Cited by 209 · see citing works

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia

Pospı́šilová, Š., de Castro, D. G., Malčíková, J., Trbušek, M., Rossi, D., Kater, A. P., Cymbalista, F., Eichhorst, B. F., Hallek, M. J., Döhner, H., et al. (2012) · Leukemia · doi:10.1038/leu.2012.25 · Cited by 188 · see citing works

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

Kennedy, B., Rawstron, A. C., Carter, C., Ryan, M. K., Speed, K., Lucas, G. S., & Hillmen, P. (2002) · Blood · doi:10.1182/blood.v99.6.2245 · Cited by 186 · see citing works

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Hale, G., Rebello, P., Brettman, L. R., Fegan, C., Kennedy, B., Kimby, E. K., Leach, M., Lundin, J., Mellstedt, H., Moreton, P., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0593 · Cited by 181 · see citing works

Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

Xia, M., Tone, M., Packman, L. C., Hale, G., & Waldmann, H. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210714 · Cited by 168 · see citing works

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J. M., Dodd, S. R., Oates, M., Johnson, G. G., Schuh, A., Matutes, E., Dearden, C. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.9695 · Cited by 163 · see citing works

Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

Buggins, A. G. S., Mufti, G. J., Salisbury, J. R., Codd, J. D., Westwood, N., Arno, M. J., Fishlock, K., Pagliuca, A., & Devereux, S. (2002) · Blood · doi:10.1182/blood.v100.5.1715.h81702001715_1715_1720 · Cited by 137 · see citing works

PI3Kδ Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

Fruman, D. A., & Rommel, C. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0249 · Cited by 137 · see citing works

Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia

Bowen, A., Zomas, A., Emmett, E., Matutes, E., Dyer, M. J. S., & Catovsky, D. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2061.x · Cited by 129 · see citing works

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S. H., Kurzrock, R., Lerner, S. A., Kontoyiannis, D. P., & Keating, M. J. (2003) · Cancer · doi:10.1002/cncr.11551 · Cited by 127 · see citing works

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Lundin, J., Porwit-MacDonald, A., Rossmann, E. D., Karlsson, C., Edman, P., Rezvany, M. R., Kimby, E., Österborg, A., & Mellstedt, H. (2004) · Leukemia · doi:10.1038/sj.leu.2403258 · Cited by 118 · see citing works

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

Mone, A. P., Cheney, C. M., Banks, A. L., Tridandapani, S., Mehter, N. S., Guster, S. E., Lin, T. S., Eisenbeis, C. F., Young, D. C., & Byrd, J. C. (2005) · Leukemia · doi:10.1038/sj.leu.2404014 · Cited by 115 · see citing works

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen

Meng-Qi, X., Hale, G., & Waldmann, H. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90155-5 · Cited by 110 · see citing works

How I treat refractory CLL

Montserrat, E., Moreno, C., Esteve, J., Urbano-Ispizúa, Á., Giné, E., & Bosch, F. (2005) · Blood · doi:10.1182/blood-2005-02-0819 · Cited by 94 · see citing works

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial

Leprêtre, S., Aurran, T., Mahé, B., Cazin, B., Tournilhac, O., Maisonneuve, H., Casasnovas, O., Delmer, A. J., Leblond, V., Royer, B., et al. (2012) · Blood · doi:10.1182/blood-2011-07-365437 · Cited by 93 · see citing works

Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab

O'Brien, S. M., Keating, M. J., & Mocarski, E. S. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.049 · Cited by 93 · see citing works

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

Elter, T., Gercheva, L., Pylylpenko, H., Robak, T., Jaksic, B. S., Rekhtman, G. B., Kyrcz‐Krzemień, S., Vatutin, M. T., Wu, J., Sirard, C. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70242-x · Cited by 92 · see citing works

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

Österborg, A., Foà, R., Bezares, R. F., Dearden, C. E., Dyer, M. J. S., Geisler, C. H., Lin, T. S., Montillo, M., van Oers, M. H. J., Wendtner, C. ‐., et al. (2009) · Leukemia · doi:10.1038/leu.2009.146 · Cited by 89 · see citing works

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

O'Brien, S. M., Ravandi, F., Riehl, T., Wierda, W. G., Huang, X., Tarrand, J. J., O’Neal, B., Kantarjian, H. M., & Keating, M. J. (2007) · Blood · doi:10.1182/blood-2007-03-080010 · Cited by 88 · see citing works

Effect of alemtuzumab on neoplastic B cells.

Golay, J., Manganini, M., Rambaldi, A., & Introna, M. (2004) · PubMed · Cited by 86 · see citing works

Phase II Trial

Graham‐Pole, J. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-8-199404150-00013 · Cited by 85 · see citing works

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

Pettitt, A. R., Matutes, E., & Oscier, D. G. (2006) · Leukemia · doi:10.1038/sj.leu.2404265 · Cited by 84 · see citing works

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity

Nückel, H., Frey, U. H., Röth, A., Dührsen, U., & Siffert, W. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.024 · Cited by 84 · see citing works

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies

Dyer, M. J. S., Hale, G., Marcus, R. E., & Waldmann, H. (1990) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199009053522 · Cited by 71 · see citing works

A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

Nabhan, C., Patton, D. R., Gordon, L. I., Riley, M. C., Kuzel, T. M., Tallman, M. S., & Rosen, S. T. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331286096 · Cited by 68 · see citing works

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

Rawstron, A. C., Kennedy, B., Moreton, P., Dickinson, A. J., Cullen, M. J., Richards, S. J., Jack, A., & Hillmen, P. (2003) · Blood · doi:10.1182/blood-2002-10-3270 · Cited by 66 · see citing works

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Badoux, X. C. A., Keating, M. J., Wang, X., O'Brien, S. M., Ferrajoli, A., Faderl, S. H., Burger, J. A., Koller, C. A., Lerner, S. A., Kantarjian, H. M., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341032 · Cited by 62 · see citing works

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

O'Brien, S. M., Burger, J. A., Blum, K. A., Furman, R. R., Coutre, S. E., Sharman, J. P., Flinn, I. W., Grant, B., Heerema, N. A., Johnson, A. J., et al. (2011) · Blood · doi:10.1182/blood.v118.21.983.983 · Cited by 57 · see citing works

The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53.

Osuji, N., Giudice, I. D., Matutes, E., Wotherspoon, A. C., Dearden, C. E., & Catovsky, D. (2005) · PubMed · Cited by 55 · see citing works

Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans.

Hale, G., Dm, S., Fg, H., & Waldmann, H. (1983) · PubMed · Cited by 55 · see citing works

Alemtuzumab for patients with chronic lymphocytic leukaemia

Skoetz, N., Bauer, K. H., Elter, T., Monsef, I., Roloff, V., Hallek, M. J., & Engert, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008078.pub2 · Cited by 51 · see citing works

Routine clinical use of alemtuzumab in patients with heavily pretreated B‐cell chronic lymphocytic leukemia

Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S. A., Zabernigg, A. F., Bauer, F., Haslbauer, F., Demirtas, D., Grossschmidt, P., Tatzreiter, G., et al. (2006) · Cancer · doi:10.1002/cncr.22263 · Cited by 42 · see citing works

Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Faderl, S., Ferrajoli, A., Wierda, W. G., O'Brien, S. M., Lerner, S. A., & Keating, M. J. (2010) · Cancer · doi:10.1002/cncr.24958 · Cited by 42 · see citing works

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

Cortelezzi, A., Pasquini, M. C., Gardellini, A., Gianelli, U., Bossi, A., Reda, G., Sarina, B., Musto, P., Barcellini, W., Neri, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.148 · Cited by 38 · see citing works

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia

Lin, T. S., Flinn, I. W., Lucas, M. S., Porcu, P., Sickler, J., Moran, M. E., Lucas, D. M., Heerema, N. A., Grever, M. R., & Byrd, J. C. (2005) · Leukemia · doi:10.1038/sj.leu.2403782 · Cited by 36 · see citing works

Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.

O'Brien, S. M., Barrientos, J. C., Flinn, I. W., Barr, P. M., Burger, J. A., Navarro, T., James, D. F., Hedrick, E. E., Friedberg, J. W., & Brown, J. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6515 · Cited by 36 · see citing works

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first‐line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Hainsworth, J. D., Vázquez, E. R., Spigel, D. R., Raefsky, E. L., Bearden, J. D., Saez, R. A., & Greco, F. A. (2008) · Cancer · doi:10.1002/cncr.23271 · Cited by 34 · see citing works

Novel therapies for chronic lymphocytic leukemia in the 21st century.

Byrd, J. C., Waselenko, J. K., Keating, M., Rai, K., & Grever, M. R. (2000) · PubMed · Cited by 33 · see citing works

Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL)

Thiéblemont, C., Bouafia, F., Hornez, E., Dumontet, C., Tartas, S., Antal, D., Lemieux, B., Traullé, C., Espinouse, D., Salles, G., et al. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001615675 · Cited by 31 · see citing works

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

Karlsson, C., Lundin, J., Kimby, E. K., Kennedy, B., Moreton, P., Hillmen, P., & Österborg, A. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07451.x · Cited by 31 · see citing works

Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed?

Rieger, K., von Grünhagen, U., Fietz, T. J., Thiel, E., & Knauf, W. U. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190310001598017 · Cited by 30 · see citing works

An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia

Montillo, M., Tedeschi, A., Petrizzi, V. B., Ricci, F., Crugnola, M., Spriano, M., Spedini, P., Ilariucci, F., Uziel, L., Attolico, I., et al. (2011) · Blood · doi:10.1182/blood-2011-05-351833 · Cited by 29 · see citing works

Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma

Lim, S., Davey, G., & Marcus, R. E. (1993) · The Lancet · doi:10.1016/0140-6736(93)93024-u · Cited by 28 · see citing works

A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.

Cortelezzi, A., Pasquini, M. C., Sarina, B., Bertani, G., Grifoni, F. I., Colombi, M., & Deliliers, G. L. (2005) · PubMed · Cited by 28 · see citing works

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories

Fiegl, M., Erdel, M., Tinhofer, I., Brychtová, Y., Panovská, A., Doubek, M., Eigenberger, K., Fonatsch, C., Hopfinger, G., Mühlberger, H., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq236 · Cited by 27 · see citing works

Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine – Interim Analysis of the CLL2O Trial of the GCLLSG and FCGCLL/MW

Stilgenbauer, S., Cymbalista, F., Leblond, V., Delmer, A. J., Zenz, T., Winkler, D. F. H., Bühler, A., Mack, S., Busch, R. M., Ibach, S., et al. (2010) · Blood · doi:10.1182/blood.v116.21.920.920 · Cited by 27 · see citing works

Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.

Gorkom, B. A. P. L., Huisman, C. A. M., Wijermans, P., & Schipperus, M. R. (2007) · PubMed · Cited by 24 · see citing works

Reconstitution of the T‐cell repertoire following treatment with alemtuzumab (anti‐CD52 monoclonal antibody) in patients with B‐cell chronic lymphocytic leukaemia

Rezvany, M. R., Jeddi‐Tehrani, M., Karlsson, C., Lundin, J., Rabbani, H., Österborg, A., & Mellstedt, H. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06324.x · Cited by 23 · see citing works

Resistance to Chemotherapy

Basile, K. J., & Aplin, A. E. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00010-5 · Cited by 23 · see citing works

Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.

Cheson, B. D. (2009) · PubMed · Cited by 20 · see citing works

An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Cortelezzi, A., Gritti, G., Laurenti, L., Cuneo, A., Ciolli, S., Renzo, N. D., Musto, P., Mauro, F. R., Cascavilla, N., Falchi, L., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08965.x · Cited by 17 · see citing works

Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia

Elter, T., James, R., Busch, R., Winkler, D. F. H., Ritgen, M., Böttcher, S., Kahl, C., Gassmann, W., Stauch, M. B., Hasan, I., et al. (2012) · Leukemia · doi:10.1038/leu.2012.129 · Cited by 17 · see citing works

Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

Vallejo, C. T., Ríos, E., de la Serna, J., Jarque, I., Ferra, C. M., Sánchez‐Godoy, P., Solano, C., de la Cámara, R., Rosell, A., Varela, R., et al. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.77 · Cited by 17 · see citing works

Erratum: Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence

Faderl, S., Ferrajoli, A., Wierda, W. G., O'Brien, S. M., Lerner, S. A., & Keating, M. J. (2010) · Cancer · doi:10.1002/cncr.25434 · Cited by 14 · see citing works

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis

Bezares, R. F., Stemmelin, G. R., Diaz, A., Argentieri, D., Zubiaur, E. L., Garay, G. E., Bartomioli, M., Ryser, R., & Milone, G. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.584991 · Cited by 12 · see citing works

Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

Gritti, G., Reda, G., Maura, F., Piciocchi, A., Baldini, L., Molica, S., Neri, A., & Cortelezzi, A. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.623258 · Cited by 12 · see citing works

Alemtuzumab in clinical practice: A British Columbia experience

Hui, D., Lam, W., Toze, C. L., Delorme, M., Noble, M. C., Klimo, P., Sutherland, J., Gill, K. K., Connors, J. M., & Sehn, L. H. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701760029 · Cited by 11 · see citing works

Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.

Laurenti, L., Piccioni, P., Tarnani, M., Efremov, D. G., Fiorini, A., Garzia, M., & Sica, S. (2005) · PubMed · Cited by 11 · see citing works

Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia

Kaufman, M. S., Caramanica, A., Janson, D., Driscoll, N., Johnson, C., Kohn, N. E., Wasil, T., & Rai, K. R. (2010) · Medical Oncology · doi:10.1007/s12032-010-9478-3 · Cited by 9 · see citing works

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients

for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, I. C. W. T. C. L. S. G. F. L., Fiegl, M., Falkner, F., Steurer, M., Zojer, N., Hopfinger, G., Haslbauer, F., Winder, G., Voskova, D., Andel, J., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1192-5 · Cited by 8 · see citing works

FCA: Forget Chemoimmunotherapy with Alemtuzumab?

Hallek, M. J. (2012) · Blood · doi:10.1182/blood-2012-04-413096 · Cited by 8 · see citing works

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia

Ferrajoli, A., Wierda, W. G., LaPushin, R., O'Brien, S. M., Faderl, S., Browning, M., & Keating, M. J. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.01023.x · Cited by 8 · see citing works

Milnacipran versus other anti-depressive agents for depression (Protocol)

Imperadore, G., Cipriani, A., Signoretti, A., Furukawa, T. A., Watanabe, N., Churchill, R. C., McGuire, F. H., & Barbui, C. (2007) · Cochrane Database of Systematic Reviews · Cited by 8 · see citing works

High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission

Majolino, I., Ladetto, M., Locasciulli, A., Drandi, D., Benedetti, F. M., Gallamini, A., Chisesi, T., Blasio, A. D., Boccadoro, M., & Tarella, C. (2006) · Medical Oncology · doi:10.1385/mo:23:3:359 · Cited by 7 · see citing works

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Varghese, A. M., Sayala, H. A., Moreton, P., Jones, R. A., Rawstron, A. C., Sheila, J., Evans, P., Carter, A., Dearden, C. E., Matutes, E., et al. (2010) · Blood · doi:10.1182/blood.v116.21.922.922 · Cited by 6 · see citing works

The BENDALEM CLL 6 AGMT Study – Bendamustine Combined with Alemtuzumab In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis

Egle, A., Melchardt, T., Weiß, L., Steurer, M., & Greil, R. (2010) · Blood · doi:10.1182/blood.v116.21.4633.4633 · Cited by 5 · see citing works

Analysis of Minimal Residual Disease (MRD) from the Phase 2 Multicenter Study of Subcutaneous (SC) Alemtuzumab Combined with Fludarabine for Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (CLL).

Flowers, C. R., Rosenthal, H., Brown, J. R., Stock, W., Katzen, H. I., Lakhanpal, S., & Jaye, D. L. (2007) · Blood · doi:10.1182/blood.v110.11.3111.3111 · Cited by 5 · see citing works

New modalities of therapy in chronic lymphocytic leukemia

Cheson, B. D. (1991) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(91)90019-9 · Cited by 4 · see citing works

5.24 Pentostatin, Alemtuzumab, and Low-Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Zent, C. S., LaPlant, B. R., Link, B. K., Call, T. G., Shanafelt, T. D., Bowen, D. A., Kay, N. E., Weiner, G. J., & Witzig, T. E. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.09.178 · Cited by 4 · see citing works

Fludarabine and Alemtuzumab Versus Fludarabine and Rituximab in the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from a Phase II Study.

Gribben, J. G., Stephans, K. F., & Marshal, B. (2005) · Blood · doi:10.1182/blood.v106.11.5046.5046 · Cited by 3 · see citing works

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL.

Brown, J. R., Messmer, B. T., Werner, L. L., Mikler, E., Fisher, D. C., LaCasce, A. S., Armand, P. A., Jacobsen, E. D., Dalton, V., Tesar, B. M., et al. (2010) · Blood · doi:10.1182/blood.v116.21.1381.1381 · Cited by 2 · see citing works

The Alemtuzumab Treatment of Refractory to Fludarabine Chronic Lymphocytic Leukemia Patients.

Васильевна, К. Е., Golenkov, A. K., Трифонова, Е. В., & Буравцова, И. В. (2009) · Blood · doi:10.1182/blood.v114.22.4415.4415 · Cited by 1 · see citing works

BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL

Tedeschi, A., Coscia, M., Rossi, D., Ricci, F., D'Arena, G. F., Orlandi, E. M., Petrizzi, V. B., Scarfò, L., Vitale, C., Vismara, E., et al. (2011) · IrInSubria (University of Insubria) · Cited by 1 · see citing works

Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)

Zent, C. S., LaPlant, B. R., Link, B. K., Call, T. G., Shanafelt, T. D., Bowen, D. A., Kay, N. E., Weiner, G. J., & Witzig, T. E. (2011) · Blood · doi:10.1182/blood.v118.21.1790.1790 · Cited by 1 · see citing works

Exploring treatment options in cancer: tumor treatment strategies

Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201 · see citing works

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works

Guidelines on the use of irradiated blood components

Foukaneli, T., Kerr, P., Bolton‐Maggs, P. H. B., Cardigan, R. A., Coles, A. J., Gennery, A. R., Jane, D., Kumararatne, D. S., Manson, A. L., New, H. V., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17015 · Cited by 113 · see citing works

Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML

Herrmann, H., Sadovnik, I., Eisenwort, G., Rülicke, T., Blatt, K., Herndlhofer, S., Willmann, M., Stefanzl, G., Baumgartner, S., Greiner, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001742 · Cited by 109 · see citing works

Therapeutic Monoclonal Antibodies against Cancer: Present and Future

Delgado, M., & García‐Sanz, J. A. (2023) · Cells · doi:10.3390/cells12242837 · Cited by 73 · see citing works

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)

Fernández‐Ruiz, M., Meije, Y., Manuel, O., Akan, H., Carratalà, J., Aguado, J. M., & Delaloye, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.029 · Cited by 72 · see citing works

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness

Corraliza-Gorjón, I., Somovilla-Crespo, B., Santamaría, S. S., García‐Sanz, J. A., & Kremer, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01804 · Cited by 68 · see citing works

Monoclonal Antibodies as Neurological Therapeutics

Gklinos, P., Papadopoulou, M., Stanulović, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 62 · see citing works

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Ronson, A., Tvito, A., & Rowe, J. M. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0519-8 · Cited by 53 · see citing works

Bidirectional epigenetic editing reveals hierarchies in gene regulation

Pacalin, N. M., Steinhart, Z., Shi, Q., Belk, J. A., Dorovskyi, D., Kraft, K., Parker, K. R., Shy, B. R., Marson, A., & Chang, H. Y. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02213-3 · Cited by 48 · see citing works

Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies

Masuyama, J., Murakami, T., Iwamoto, S., & Fujita, S. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.011 · Cited by 45 · see citing works

Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice

Dailah, H. G., Hommdi, A. A., Koriri, M. D., Algathlan, E. M., & Mohan, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24559 · Cited by 38 · see citing works

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors

Charmsaz, S., Scott, A. M., & Boyd, A. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.003 · Cited by 29 · see citing works

Novel Drug Therapies in Myeloid Leukemia: a Patent Review

Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 16 · see citing works

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place

Shallis, R. M., Chokr, N., Stahl, M. F., Pine, A. B., & Zeidan, A. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1503049 · Cited by 15 · see citing works

Radioimmunoconjugates in the age of modern immuno-oncology

Nasr, D., Kumar, P. A., Zerdan, M. B., Ghelani, G. H., Dutta, D., Graziano, S. L., & Lim, S. H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121126 · Cited by 14 · see citing works

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies

Smolewski, P., Robak, P. J., Cebula‐Obrzut, B., Misiewicz, M., Mędra, A., Majchrzak, A., Witkowska, M., Stromatt, S. C., & Robak, T. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.021 · Cited by 11 · see citing works

Current evaluation of alemtuzumab in multiple sclerosis

Coyle, P. K. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.866084 · Cited by 10 · see citing works

In Pursuit of an Effective Treatment: the Past, Present and Future of Clinical Trials in Inclusion Body Myositis

Snedden, A. M., Lilleker, J. B., & Chinoy, H. (2021) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-020-00169-4 · Cited by 10 · see citing works

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL

D’Rozario, J., & Bennett, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719844697 · Cited by 6 · see citing works

Therapeutic applications and strategies of neurobiomarkers in neurological disorders: A narrative review

Kumar, P., Chaudhary, B., Devi, S., Dubey, G., Chatterjee, A., Sharma, D., & Gupta, M. M. (2025) · NeuroMarkers. · doi:10.1016/j.neumar.2025.100113 · Cited by 4 · see citing works

Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab

Niscola, P., Ragusa, D., Scaramucci, L., Giovannini, M., Piccioni, D., Tendas, A., Perrotti, A. P., de Fabritiis, P., & Poeta, G. D. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1877-z · Cited by 3 · see citing works

Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?

Ayoub, M., Susín, S. A., & Bauvois, B. (2024) · Cancers · doi:10.3390/cancers17010072 · Cited by 2 · see citing works

Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics

Moia, R., Patriarca, A., Mahmoud, A. M., Ferri, V., Favini, C., Rasi, S., Deambrogi, C., & Gaïdano, G. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1804860 · Cited by 2 · see citing works

Next Generation Sequencing as a Method for Discovering the Nature of Chronic Lymphocytic Leukemia and Transition to Personalized Treatment

Mikhaleva, M., Мартынкевич, И. С., Buldakov, I., Петров, С. В., Motyko, E., Кувшинов, А. Ю., Bogdanov, A. N., & Волошин, С. В. (2021) · Гематология Трансфузиология Восточная Европа · doi:10.34883/pi.2021.7.2.006 · Cited by 1 · see citing works

Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate

Lepetit, M., & Laplaud, D. A. (2016) · EMC - Neurologia · doi:10.1016/s1634-7072(16)78802-7

Overview of the Risk of Infection Associated with Biologic and Target Therapies

Fernández‐Ruiz, M. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_1

Monoclonal Antibodies and Cancer

Ali, S. R., Saxena, G., Jamir, L., Ahmed, N., Singh, G. K., Bhat, H. R., Ghosh, S. K., & Shakya, A. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_11

Monoclonal Antibodies Against Human Immunodeficiency Virus (HIV): Current Opinion

Senthilkumar, H., Dhamodharan, P., Eshak, D., Chandrasekaran, S. D., & Arumugam, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-77911-4_4

Antibody Therapy

Woodford, R. G., & Lim, K. H. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00236-2

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions

Burt, R. K., & Alexander, T. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90887-0.00020-1

A Pilot Trial of Rituximab and Alemtuzumab Combination Therapy in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)

Nabhan, C., Patton, D. R., Gordon, L. I., Riley, M. C., Kuzel, T. M., Tallman, M. S., & Rosen, S. T. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190412331286096 · Cited by 68 · see citing works

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Schweighofer, C. D. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s3099 · Cited by 20 · see citing works

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Montillo, M., Tedeschi, A., Gaïdano, G., Coscia, M., Petrizzi, V. B., Orlandi, E. M., Cascavilla, N., Ghia, P., Motta, M., Gallamini, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.106740 · Cited by 5 · see citing works

Alemtuzumab in the treatment of relapsed chronic lymphocytic leukaemia - a report of three cases

Wróbel, T., Mazur, G. J., Kazanowska, K., & Kuliczkowski, K. (2004) · Nowotwory Journal of Oncology

Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients

Sylvan, S. E., Lundin, J., Ipek, M., Palma, M., Karlsson, C., & Hansson, L. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2105-1 · Cited by 8 · see citing works